About this medicine
Product information is provided to support understanding and conversations with your care team. Follow the approved leaflet and your prescriber’s instructions.
Content migrated from the company website; pending clinical review before final publication.
Dosage forms
Oral tablets (100 mg)
Drug class
Tyrosine kinase inhibitor
Administration
Take with food and a glass of water to reduce gastrointestinal irritation. It is recommended that daily doses above 800 mg be divided into two doses. If needed, tablets may be dissolved in water and taken immediately.
Uses
• Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML)
• Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL)
• Gastrointestinal stromal tumors (GIST) after surgery
• Unresectable or malignant metastatic disease
• Myelodysplastic/myeloproliferative disease with PDGFR gene rearrangements
• Hypereosinophilic syndrome (HES) or chronic eosinophilic leukemia (CEL)
• Dermatofibrosarcoma protuberans
• Aggressive systemic mastocytosis (Aggressive Systemic Macrocytosis)
Competitive advantages
As the first BCR-ABL tyrosine kinase inhibitor, imatinib brought a major change to the treatment of chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST). This medicine not only substantially inhibits disease progression but also improves patients’ quality of life.
Original company product page ↗